GH Guardant Health, Inc.
Guardant Health, Inc. (GH) trend channel, buy level and 3-month target on Trade The Path. Sector: Healthcare. Listed on NASDAQ. Levels below are fitted to this ticker's own swing highs and lows (Theil–Sen, log-price), then projected 3 months. If this ticker has no settled sample yet, treat the numbers as a geometric read, not a track record. Information only, not financial advice.
In the sell zone
Price has run up to the upper trend line — the level it has repeatedly stalled at.
Read from the last 18 months of history we hold: rising, drifting more than +100% a year. Price is above both fitted ceilings, so there is no line overhead to break — and no fitted resistance to price the target against either. What would overturn this: a close below US$112.08 — the floor of the channel being read — after which the trend, not the entry, is what was wrong.
- 18 months read from
- US$112.08 – US$173.11 Rising channel, more than +100% a year
- Position in that channel
- 103% above the ceiling of it — 0% is the floor, 100% the ceiling
Price history, with the path projected 3 months forward
- Daily close
- Upper trend line (18 months)
- Lower trend line (18 months)
- Dashed after today: projected 3 months
- Our buy
- Our target
Our target
No published call today because price has already run past what this setup aims at, so there is nothing left of the move to buy. No alerts are sent. The buy and target below are still this site's read of the fitted channel.
Buy at or below
US$112.12
level as at 17 Sept 2026
Our target
US$173.66
by 16 Dec 2026
Projected move
54.9%
gross, before costs
Price is at or through our target.
- Upper line touches
- 3
- Lower line touches
- 3
- Fit confidence
- 41%
- Fitted
- 16 Sept 2026
About Guardant Health, Inc.
Guardant Health, Inc., established in Redwood City, California, in 2011, is a precision oncology company that delivers a range of diagnostic blood tests, comprehensive data sets, and advanced analytical solutions both within the United States and internationally. For patients with advanced-stage cancer, the company's core offerings include several liquid biopsy-based tests such as Guardant360 (available in LDT and CDx versions) and GuardantOMNI. Complementing these diagnostic tools, Guardant Health also provides GuardantINFORM, an in-silico research platform leveraging an extensive clinical-genomic liquid biopsy dataset derived from advanced cancer patients. Innovation is a key focus, with the company currently developing the LUNAR-2 test, designed for the early detection of colorectal cancer in eligible asymptomatic individuals. Another emerging solution in development is GuardantConnect, an integrated software platform intended to link biopharmaceutical and clinical clients by connecting patients whose Guardant360 tests reveal actionable alterations with potentially relevant clinical trials. Furthermore, Guardant Health offers the Guardant Reveal Test, which aids in selecting neoadjuvant and adjuvant treatments for early-stage cancer patients. Its portfolio also includes a Guardant360 product for tissue genotyping and Guardant-19 for novel coronavirus detection. The company extends its expertise to biopharmaceutical companies and medical institutions through various development services, encompassing companion diagnostic development, regulatory approval support, clinical study management (including setup, monitoring, and maintenance), testing development, and kit fulfillment.
- Sector
- Healthcare
- Industry
- Medical - Diagnostics & Research
- CEO
- Helmy Eltoukhy
- Employees
- 2,498
- Country
- US
Scorecard
Our own pillar scores, computed from the fundamentals below. They are not Morningstar ratings — that data is licensed and we do not redistribute it.
- Valuation
- —
- Profitability
- —
- Financial health
- —
- Cash generation
- —
Key statistics
- Market cap
- US$21.67B
- Enterprise value
- —
- Beta
- 1.59
- Avg volume
- 2.49M
- Revenue per share
- —
- Dividend yield
- —
- 52-week range
- 53.4-176.58
- Exchange
- NASDAQ
Key ratios
- P/E (TTM)
- —
- PEG
- —
- Price / sales
- —
- Price / book
- —
- EV / EBITDA
- —
- Gross margin
- —
- Operating margin
- —
- Net margin
- —
- Current ratio
- —
- Quick ratio
- —
- Debt / equity
- —
- Interest cover
- —
Income statement
Balance sheet
Cash flow
Trend lines are fitted statistically to past swing highs and lows and projected forward on the assumption the same rhythm continues. It often does not. This is information, not advice.